P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

NTP Study Number:	C20313B
Lock Date:	03/06/2013
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	3.0.2.3_002
PWG Approval Date:	NONE

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF ACRYLAMIDE

MALE RATS

Organ

Epididymis

Liver

Liver: Left Lateral Lobe Lung: Alveolus Peripheral Nerve: Axon Peripheral Nerve: Schwann Cell Preputial Gland

Skeletal Muscle Testes: Germinal Epithelium

FEMALE RATS

Organ

Liver Liver: Left Lateral Lobe Ovary Peripheral Nerve: Axon Peripheral Nerve: Schwann Cell Skeletal Muscle Urinary Bladder Uterus

Morphology

Exfoliated Germ Cell Hypospermia Tension Lipidosis Developmental Malformation Hemorrhage Degeneration Degeneration Inflammation Inflammation Chronic Atrophy Degeneration

Morphology

Hepatodiaphragmatic Nodule Developmental Malformation Cyst Degeneration Degeneration Atrophy Dilatation Dilatation

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Adrenal Cortex Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	2/8 (25%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	2/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	25%	0%	0%	0%	0%	0%
TERMINAL (d)	2/8 (25%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.223N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.223N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.223N
COCH-ARM / FISHERS	P=0.145N	(e)	(e)	(e)	(e)	P=0.233N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.063N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Bone Marrow Atrophy Focal						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Epididymis Exfoliated Germ Cell						
LESION RATES						
OVERALL (a)	0/8 (0%)	1/8 (13%)	0/8 (0%)	3/8 (38%)	8/8 (100%)	8/8 (100%)
POLY-3 RATE (b)	0/8.00	1/8.00	0/8.00	3/8.00	8/8.00	8/8.00
POLY-3 PERCENT (g)	0%	12.5%	0%	37.5%	100%	100%
TERMINAL (d)	0/8 (0%)	1/8 (13%)	0/8 (0%)	3/8 (38%)	8/8 (100%)	8/8 (100%)
FIRST INCIDENCE		101 (T)		101 (T)	101 (T)	101 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.500	(e)	P=0.086	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.500	(e)	P=0.086	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.500	(e)	P=0.086	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.500	(e)	P=0.100	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.158	(e)	P=0.020*	(e)	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Epididymis Hypospermia						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/8 (0%)	0/8 (0%)	0/8 (0%)	0/8 (0%)	4/8 (50%)
POLY-3 RATE (b)	0/8.00	0/8.00	0/8.00	0/8.00	0/8.00	4/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	50%
TERMINAL (d)	0/8 (0%)	0/8 (0%)	0/8 (0%)	0/8 (0%)	0/8 (0%)	4/8 (50%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.024*
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.024*
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.024*
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.038*
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	P=0.004**

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Eye: Retina Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Harderian Gland Inflammation Chronic						
LESION RATES						
OVERALL (a)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
POLY-3 RATE (b)	1/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	12.5%
TERMINAL (d)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
FIRST INCIDENCE	101 (T)					101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.760
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.760
COCH-ARM / FISHERS	P=0.675	(e)	(e)	(e)	(e)	P=0.767N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Heart: Myocardium Inflammation Focal						
LESION RATES						
OVERALL (a)	3/8 (38%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
POLY-3 RATE (b)	3/8.00	0/0.00	0/0.00	0/0.00	0/0.00	2/8.00
POLY-3 PERCENT (g)	37.5%	0%	0%	0%	0%	25%
TERMINAL (d)	3/8 (38%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
FIRST INCIDENCE	101 (T)					101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.415N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.304N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Kidney: Cortex Mineralization						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Kidney: Renal Tubule Hyperplasia						
LESION RATES						
OVERALL (a)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	1/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	0%
TERMINAL (d)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.340N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Liver Hepatodiaphragmatic Nodu	le					
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	1/8 (13%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/1.00	0/0.00	0/1.00	1/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	1/8 (13%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.295	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl N
iver nfiltration Cellular Lymphod	cyte					
LESION RATES						
OVERALL (a)	1/8 (13%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	1/8.00	0/1.00	0/1.00	0/0.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	0%
TERMINAL (d)	1/8 (13%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	P=0.878N	P=0.878N	(e)	P=0.878N	P=0.500N
POLY 1.5	(e)	P=0.878N	P=0.878N	(e)	P=0.878N	P=0.500N
POLY 6	(e)	P=0.878N	P=0.878N	(e)	P=0.878N	P=0.500N
COCH-ARM / FISHERS	P=0.374N	P=0.889N	P=0.889N	(e)	P=0.889N	P=0.500N
MAX-ISO-POLY-3	(e)	P=0.399N	P=0.399N	(e)	P=0.399N	P=0.158N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Liver Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/1.00	0/0.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Liver Necrosis Focal						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	2/8 (25%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/1.00	0/0.00	0/1.00	2/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	25%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	2/8 (25%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.223
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.223
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.223
COCH-ARM / FISHERS	P=0.105	(e)	(e)	(e)	(e)	P=0.233
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.063

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Liver Tension Lipidosis						
LESION RATES						
OVERALL (a)	0/8 (0%)	1/1 (100%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	1/1.00	0/1.00	0/0.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	0%	100%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	1/1 (100%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE		101 (T)				
STATISTICAL TESTS						
POLY 3	(e)	P=0.111	(e)	(e)	(e)	(e)
POLY 1.5	(e)	P=0.111	(e)	(e)	(e)	(e)
POLY 6	(e)	P=0.111	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.407N	P=0.111	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	(e)	(e)	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Liver Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/1.00	0/0.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/1 (0%)	0/0 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl N
Liver: Left Lateral Lobe Developmental Malformation	n					
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/1.00	1/1.00	0/0.00	1/1.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	100%	0%	100%	0%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/8 (0%)
FIRST INCIDENCE			101 (T)		101 (T)	
STATISTICAL TESTS						
POLY 3	(e)	(e)	P=0.111	(e)	P=0.111	(e)
POLY 1.5	(e)	(e)	P=0.111	(e)	P=0.111	(e)
POLY 6	(e)	(e)	P=0.111	(e)	P=0.111	(e)
COCH-ARM / FISHERS	P=0.438N	(e)	P=0.111	(e)	P=0.111	(e)
MAX-ISO-POLY-3	(e)	(e)	P<0.001**	(e)	P<0.001**	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Lung: Alveolus Hemorrhage						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/8 (38%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	3/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	37.5%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/8 (38%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.086
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.086
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.086
COCH-ARM / FISHERS	P=0.062	(e)	(e)	(e)	(e)	P=0.100
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.020*

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Lung: Alveolus Inflammation Focal						
LESION RATES						
OVERALL (a)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	1/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	0%
TERMINAL (d)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.340N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Mesentery: Fat Necrosis						
LESION RATES						
OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Peripheral Nerve: Axon Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	8/8 (100%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/8.00	8/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	100%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	8/8 (100%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	(e)	(e)	(e)	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl N
Peripheral Nerve: Schwann Degeneration	Cell					
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	8/8 (100%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/8.00	8/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	100%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	8/8 (100%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	(e)	(e)	(e)	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Pituitary Gland: Pars Distalis Cyst						
LESION RATES						
OVERALL (a)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	1/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	0%
TERMINAL (d)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.340N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Preputial Gland Inflammation						
LESION RATES						
OVERALL (a)	3/8 (38%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	3/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	37.5%	0%	0%	0%	0%	0%
TERMINAL (d)	3/8 (38%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.086N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.086N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.086N
COCH-ARM / FISHERS	P=0.062N	(e)	(e)	(e)	(e)	P=0.100N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.020N*

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

	Males								
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M			
Preputial Gland Inflammation Chronic									
LESION RATES									
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/8 (75%)			
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	6/8.00			
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	75%			
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	6/8 (75%)			
FIRST INCIDENCE						101 (T)			
STATISTICAL TESTS									
POLY 3	(e)	(e)	(e)	(e)	(e)	P<0.001**			
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P<0.001**			
POLY 6	(e)	(e)	(e)	(e)	(e)	P<0.001**			
COCH-ARM / FISHERS	P=0.003**	(e)	(e)	(e)	(e)	P=0.003**			
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P<0.001**			

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Prostate Inflammation Chronic						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.340	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

	Males								
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M			
Skeletal Muscle Atrophy									
LESION RATES									
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	8/8 (100%)			
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/8.00	8/8.00			
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	100%			
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	8/8 (100%)			
FIRST INCIDENCE						101 (T)			
STATISTICAL TESTS									
POLY 3	(e)	(e)	(e)	(e)	(e)	P<0.001**			
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P<0.001**			
POLY 6	(e)	(e)	(e)	(e)	(e)	P<0.001**			
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**			
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)			

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Spinal Cord, Lumbar: Axon Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Spleen Pigmentation						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	2/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	25%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
FIRST INCIDENCE						101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.223
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.223
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.223
COCH-ARM / FISHERS	P=0.145	(e)	(e)	(e)	(e)	P=0.233
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.063

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl N
Testes: Germinal Epithelium Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	2/8 (25%)	2/8 (25%)	4/8 (50%)	7/8 (88%)	8/8 (100%)
POLY-3 RATE (b)	0/8.00	2/8.00	2/8.00	4/8.00	7/8.00	8/8.00
POLY-3 PERCENT (g)	0%	25%	25%	50%	87.5%	100%
TERMINAL (d)	0/8 (0%)	2/8 (25%)	2/8 (25%)	4/8 (50%)	7/8 (88%)	8/8 (100%)
FIRST INCIDENCE		101 (T)	101 (T)	101 (T)	101 (T)	101 (T)
STATISTICAL TESTS						
POLY 3	P<0.001**	P=0.223	P=0.223	P=0.024*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.223	P=0.223	P=0.024*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.223	P=0.223	P=0.024*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.233	P=0.233	P=0.038*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.063	P=0.063	P=0.004**	P<0.001**	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Thymus Hemorrhage						
LESION RATES						
OVERALL (a)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	1/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	0%
TERMINAL (d)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE	101 (T)					
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500N
COCH-ARM / FISHERS	P=0.340N	(e)	(e)	(e)	(e)	P=0.500N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158N

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Males			
DOSE	Control Feed M	7.4 PPM Acryl M	18.5 PPM Acryl M	37 PPM Acryl M	74 PPM Acryl M	185 PPM Acryl M
Urinary Bladder Dilatation						
LESION RATES						
OVERALL (a)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/8 (38%)
POLY-3 RATE (b)	1/8.00	0/0.00	0/0.00	0/0.00	0/0.00	3/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	37.5%
TERMINAL (d)	1/8 (13%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/8 (38%)
FIRST INCIDENCE	101 (T)					101 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.286
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.286
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.286
COCH-ARM / FISHERS	P=0.209	(e)	(e)	(e)	(e)	P=0.285
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.129

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Adrenal Cortex Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

	Females								
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F			
Bone Marrow Atrophy Focal									
LESION RATES									
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)			
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00			
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%			
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)			
FIRST INCIDENCE						102 (T)			
STATISTICAL TESTS									
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500			
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500			
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500			
COCH-ARM / FISHERS	P=0.340	(e)	(e)	(e)	(e)	P=0.500			
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158			

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Clitoral Gland Inflammation						
LESION RATES						
OVERALL (a)	2/8 (25%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
POLY-3 RATE (b)	2/8.00	0/0.00	0/0.00	0/0.00	0/0.00	2/8.00
POLY-3 PERCENT (g)	25%	0%	0%	0%	0%	25%
TERMINAL (d)	2/8 (25%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
FIRST INCIDENCE	102 (T)					102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.705
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.705
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.705
COCH-ARM / FISHERS	P=0.635	(e)	(e)	(e)	(e)	P=0.715N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=1.000

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Clitoral Gland Inflammation Chronic						
LESION RATES						
OVERALL (a)	5/8 (63%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/8 (38%)
POLY-3 RATE (b)	5/8.00	0/0.00	0/0.00	0/0.00	0/0.00	3/8.00
POLY-3 PERCENT (g)	62.5%	0%	0%	0%	0%	37.5%
TERMINAL (d)	5/8 (63%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/8 (38%)
FIRST INCIDENCE	102 (T)					102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.315N
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.315N
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.315N
COCH-ARM / FISHERS	P=0.242N	(e)	(e)	(e)	(e)	P=0.310N
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.167N

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Eye: Retina Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.340	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

Females								
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F		
Harderian Gland Inflammation Chronic								
LESION RATES								
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)		
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00		
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%		
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)		
FIRST INCIDENCE						102 (T)		
STATISTICAL TESTS								
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500		
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500		
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500		
COCH-ARM / FISHERS	P=0.340	(e)	(e)	(e)	(e)	P=0.500		
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158		

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Heart: Myocardium Inflammation Focal						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.340	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

Females								
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F		
Kidney: Cortex Mineralization								
LESION RATES								
OVERALL (a)	8/8 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	8/8 (100%)		
POLY-3 RATE (b)	8/8.00	0/0.00	0/0.00	0/0.00	0/0.00	8/8.00		
POLY-3 PERCENT (g)	100%	0%	0%	0%	0%	100%		
TERMINAL (d)	8/8 (100%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	8/8 (100%)		
FIRST INCIDENCE	102 (T)					102 (T)		
STATISTICAL TESTS								
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)		
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)		
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)		
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)		
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)		

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Kidney: Renal Tubule Hyperplasia						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Liver Hepatodiaphragmatic Nodu	le					
LESION RATES						
OVERALL (a)	0/8 (0%)	1/1 (100%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	1/1.00	0/2.00	0/1.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	0%	100%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	1/1 (100%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE		102 (T)				
STATISTICAL TESTS						
POLY 3	P=0.429N	P=0.111	(e)	(e)	(e)	(e)
POLY 1.5	P=0.429N	P=0.111	(e)	(e)	(e)	(e)
POLY 6	P=0.429N	P=0.111	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.429N	P=0.111	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	(e)	(e)	(e)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Liver Infiltration Cellular Lympho	cyte					
LESION RATES						
OVERALL (a)	1/8 (13%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	1/8.00	0/1.00	0/2.00	0/1.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	12.5%	0%	0%	0%	0%	0%
TERMINAL (d)	1/8 (13%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE	102 (T)					
STATISTICAL TESTS						
POLY 3	P=0.407N	P=0.878N	P=0.763N	P=0.878N	P=0.878N	P=0.500N
POLY 1.5	P=0.407N	P=0.878N	P=0.763N	P=0.878N	P=0.878N	P=0.500N
POLY 6	P=0.407N	P=0.878N	P=0.763N	P=0.878N	P=0.878N	P=0.500N
COCH-ARM / FISHERS	P=0.394N	P=0.889N	P=0.800N	P=0.889N	P=0.889N	P=0.500N
MAX-ISO-POLY-3	P=0.149N	P=0.399N	P=0.350N	P=0.399N	P=0.399N	P=0.158N

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Liver nflammation Chronic						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	1/8 (13%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/2.00	0/1.00	0/1.00	1/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	1/8 (13%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	P=0.293	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	P=0.293	(e)	(e)	(e)	(e)	P=0.500
POLY 6	P=0.293	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.268	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	P=0.149	(e)	(e)	(e)	(e)	P=0.158

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Liver Necrosis Focal						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/2.00	0/1.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Liver Tension Lipidosis						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/2.00	0/1.00	0/1.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Liver Vacuolization Cytoplasmic						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	2/8 (25%)
POLY-3 RATE (b)	0/8.00	0/1.00	0/2.00	0/1.00	0/1.00	2/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	25%
TERMINAL (d)	0/8 (0%)	0/1 (0%)	0/2 (0%)	0/1 (0%)	0/1 (0%)	2/8 (25%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	P=0.100	(e)	(e)	(e)	(e)	P=0.223
POLY 1.5	P=0.100	(e)	(e)	(e)	(e)	P=0.223
POLY 6	P=0.100	(e)	(e)	(e)	(e)	P=0.223
COCH-ARM / FISHERS	P=0.084	(e)	(e)	(e)	(e)	P=0.233
MAX-ISO-POLY-3	P=0.056	(e)	(e)	(e)	(e)	P=0.063

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

Females								
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F		
Liver: Left Lateral Lobe Developmental Malformation	n							
LESION RATES								
OVERALL (a)	1/8 (13%)	0/1 (0%)	2/2 (100%)	1/1 (100%)	1/1 (100%)	0/8 (0%)		
POLY-3 RATE (b)	1/8.00	0/1.00	2/2.00	1/1.00	1/1.00	0/8.00		
POLY-3 PERCENT (g)	12.5%	0%	100%	100%	100%	0%		
TERMINAL (d)	1/8 (13%)	0/1 (0%)	2/2 (100%)	1/1 (100%)	1/1 (100%)	0/8 (0%)		
FIRST INCIDENCE	102 (T)		102 (T)	102 (T)	102 (T)			
STATISTICAL TESTS								
POLY 3	P=0.025N*	P=0.878N	P=0.016*	P=0.202	P=0.202	P=0.500N		
POLY 1.5	P=0.025N*	P=0.878N	P=0.016*	P=0.202	P=0.202	P=0.500N		
POLY 6	P=0.025N*	P=0.878N	P=0.016*	P=0.202	P=0.202	P=0.500N		
COCH-ARM / FISHERS	P=0.133N	P=0.889N	P=0.067	P=0.222	P=0.222	P=0.500N		
MAX-ISO-POLY-3	P<0.001N**	P=0.399N	P=0.004**	P=0.040*	P=0.040*	P=0.158N		

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Lung: Alveolus Hemorrhage						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	2/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	25%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.223
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.223
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.223
COCH-ARM / FISHERS	P=0.145	(e)	(e)	(e)	(e)	P=0.233
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.063

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Lung: Alveolus Inflammation Focal						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Mesentery: Fat Necrosis						
LESION RATES						
OVERALL (a)	0/0 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	1/1.00	0/0.00	1/1.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	100%	0%	100%	0%	0%
TERMINAL (d)	0/0 (0%)	1/1 (100%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE		102 (T)		102 (T)		
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Ovary Cyst						
LESION RATES						
OVERALL (a)	0/8 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)	1/1 (100%)	3/8 (38%)
POLY-3 RATE (b)	0/8.00	1/1.00	0/0.00	0/0.00	1/1.00	3/8.00
POLY-3 PERCENT (g)	0%	100%	0%	0%	100%	37.5%
TERMINAL (d)	0/8 (0%)	1/1 (100%)	0/0 (0%)	0/0 (0%)	1/1 (100%)	3/8 (38%)
FIRST INCIDENCE		102 (T)			102 (T)	102 (T)
STATISTICAL TESTS						
POLY 3	(e)	P=0.111	(e)	(e)	P=0.111	P=0.086
POLY 1.5	(e)	P=0.111	(e)	(e)	P=0.111	P=0.086
POLY 6	(e)	P=0.111	(e)	(e)	P=0.111	P=0.086
COCH-ARM / FISHERS	P=0.193	P=0.111	(e)	(e)	P=0.111	P=0.100
MAX-ISO-POLY-3	(e)	P<0.001**	(e)	(e)	P<0.001**	P=0.020*

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Peripheral Nerve: Axon Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)	8/8 (100%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	2/8.00	8/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	25%	100%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)	8/8 (100%)
FIRST INCIDENCE					102 (T)	102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	P=0.223	P<0.001**
POLY 1.5	(e)	(e)	(e)	(e)	P=0.223	P<0.001**
POLY 6	(e)	(e)	(e)	(e)	P=0.223	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.233	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	P=0.063	(e)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Peripheral Nerve: Schwann Degeneration	Cell					
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)	8/8 (100%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	2/8.00	8/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	25%	100%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	2/8 (25%)	8/8 (100%)
FIRST INCIDENCE					102 (T)	102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	P=0.223	P<0.001**
POLY 1.5	(e)	(e)	(e)	(e)	P=0.223	P<0.001**
POLY 6	(e)	(e)	(e)	(e)	P=0.223	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.233	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	P=0.063	(e)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Pituitary Gland: Pars Distalis Cyst	5					
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Skeletal Muscle Atrophy						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	7/8 (88%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/8.00	7/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	87.5%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)	7/8 (88%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	(e)	(e)	(e)	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P<0.001**

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Spinal Cord, Lumbar: Axon Degeneration						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	1/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	12.5%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	1/8 (13%)
FIRST INCIDENCE						102 (T)
STATISTICAL TESTS						
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.500
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.500
COCH-ARM / FISHERS	P=0.340	(e)	(e)	(e)	(e)	P=0.500
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.158

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

Females								
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F		
Spleen Pigmentation								
LESION RATES								
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)		
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00		
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%		
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)		
FIRST INCIDENCE								
STATISTICAL TESTS								
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)		
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)		
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)		
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)		
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)		

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

			Females			
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F
Thymus Hemorrhage						
LESION RATES						
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	0/8.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/8 (0%)
FIRST INCIDENCE						
STATISTICAL TESTS						
POLY 3	(n)	(n)	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)	(n)	(n)

Acrylamide

CAS Number: 79-06-1

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

Females								
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F		
Urinary Bladder Dilatation								
LESION RATES								
OVERALL (a)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/7 (43%)		
POLY-3 RATE (b)	0/8.00	0/0.00	0/0.00	0/0.00	0/0.00	3/7.00		
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	42.9%		
TERMINAL (d)	0/8 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	3/7 (43%)		
FIRST INCIDENCE						102 (T)		
STATISTICAL TESTS								
POLY 3	(e)	(e)	(e)	(e)	(e)	P=0.058		
POLY 1.5	(e)	(e)	(e)	(e)	(e)	P=0.058		
POLY 6	(e)	(e)	(e)	(e)	(e)	P=0.058		
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	(e)	(e)	P=0.077		
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	P=0.013*		

Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

Females							
DOSE	Control Feed F	7.4 PPM Acryl F	18.5 PPM Acryl F	37 PPM Acryl F	74 PPM Acryl F	185 PPM Acryl F	
Uterus Dilatation							
LESION RATES							
OVERALL (a)	1/8 (13%)	1/2 (50%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	2/8 (25%)	
POLY-3 RATE (b)	1/8.00	1/2.00	0/0.00	1/1.00	0/0.00	2/8.00	
POLY-3 PERCENT (g)	12.5%	50%	0%	100%	0%	25%	
TERMINAL (d)	1/8 (13%)	1/2 (50%)	0/0 (0%)	1/1 (100%)	0/0 (0%)	2/8 (25%)	
FIRST INCIDENCE	102 (T)	102 (T)		102 (T)		102 (T)	
STATISTICAL TESTS							
POLY 3	(e)	P=0.424	(e)	P=0.202	(e)	P=0.500	
POLY 1.5	(e)	P=0.424	(e)	P=0.202	(e)	P=0.500	
POLY 6	(e)	P=0.424	(e)	P=0.202	(e)	P=0.500	
COCH-ARM / FISHERS	P=0.602	P=0.378	(e)	P=0.222	(e)	P=0.500	
MAX-ISO-POLY-3	(e)	P=0.183	(e)	P=0.040*	(e)	P=0.272	

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Acrylamide CAS Number: 79-06-1 Date Report Requested: 09/22/2016 Time Report Requested: 07:57:14 First Dose M/F: 08/09/04 / 08/09/04 Lab: NCTR

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(n)	No statistics are calculated if all dose groups have fewer than two tumors.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
Ν	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.
	*** END OF REPORT ***

Page 63